T. Rowe Price Associates’s Vera Therapeutics VERA Stock Holding History

T. Rowe Price Associates’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$184M	Sell	4,574,030 -887,946	-16%	-$38.3M	0.02%	482
2025 Q4	$277M	Buy	5,461,976 +1,795,537	+49%	+$63.8M	0.03%	367
2025 Q3	$107M	Sell	3,666,439 -813,278	-18%	-$18.8M	0.01%	607
2025 Q2	$106M	Sell	4,479,717 -275,115	-6%	-$6.19M	0.01%	559
2025 Q1	$114M	Buy	4,754,832 +377,783	+9%	+$12.1M	0.01%	530
2024 Q4	$185M	Buy	4,377,049 +437,940	+11%	+$19.4M	0.02%	448
2024 Q3	$174M	Buy	3,939,109 +318,974	+9%	+$12.1M	0.02%	456
2024 Q2	$131M	Buy	3,620,135 +1,227,106	+51%	+$48.7M	0.02%	487
2024 Q1	$103M	Buy	+2,393,029	New	+$85.3M	0.01%	544

Other funds holding VERA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

T. Rowe Price Associates's VERA Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Vera Therapeutics (VERA) stake by 16% in Q1 2026, selling an estimated $38.3M and leaving 4,574,030 shares worth $184M. The position accounts for 0.02% of the portfolio, ranked #482.

T. Rowe Price Associates first reported a position in VERA in Q1 2024 and has held it in 9 quarters since. The position peaked at $277M in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

T. Rowe Price Associates held 4,574,030 shares of Vera Therapeutics worth $184M as of Q1 2026.
T. Rowe Price Associates sold 887,946 Vera Therapeutics shares in Q1 2026, an estimated $38.3M.
Vera Therapeutics made up 0.02% of T. Rowe Price Associates's portfolio in Q1 2026, its #482 holding.
T. Rowe Price Associates first reported a position in Vera Therapeutics in Q1 2024 and has held it in 9 quarters since.
T. Rowe Price Associates's Vera Therapeutics position peaked at $277M in Q4 2025.
229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.